🇺🇸 FDA
Patent

US 9957507

Compositions and methods for inhibiting expression of mutant EGFR gene

granted A61KA61K31/713A61P

Quick answer

US patent 9957507 (Compositions and methods for inhibiting expression of mutant EGFR gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/713, A61P, A61P35/00